Erastapex
Erastapex
20 mg
Compound:
Each tablet contains:
Olmesartan medoxomil 20 mg
Auxiliary components:
Lactose monohydrate, starch, magnesium stearate, talc, titanium dioxide.
Properties:
Antihypertensive agent, angiotensin II receptor blocker. It has a high selectivity for angiotensin II type 1 receptors (AT1), with the participation of which the main effects of angiotensin II are realized. By blocking these receptors, olmesartan medoxomil prevents and eliminates the vasoconstrictive effect of angiotensin II, causes a secondary increase in plasma renin activity by eliminating negative feedback on renin release and a direct decrease in aldosterone secretion.
In arterial hypertension, olmesartan medoxomil causes a dose-dependent, prolonged decrease in blood pressure.
Indications:
Essential arterial hypertension.
Dosage and administration:
Taken orally, daily. The initial dose is 10 mg / day. With insufficient effectiveness, the dose is increased to the optimum – 20 mg / day. If necessary, the dose can be increased to a maximum of 40 mg / day.
For elderly patients, dose adjustment is not required. If it is necessary to increase the daily dose to a maximum of 40 mg / day, the increase should be carried out under careful monitoring of blood pressure.
Contraindications:
Obstruction of the biliary tract, pregnancy, breastfeeding, children and adolescents under 18 years of age, hypersensitivity to olmesartan medoxomil.
Precautionary measures:
Due to the lack of sufficient clinical experience, the use of olmesartan medoxomil is not recommended in patients with severe renal insufficiency (CC ≤20 ml / min), in patients with impaired liver function.
Use with caution in patients with aortic or mitral valve stenosis or with obstructive hypertrophic cardiomyopathy.
In the case of previous intensive diuretic therapy, adherence to a salt-free diet, with diarrhea and / or vomiting, then after taking the first dose, arterial hypotension may develop as a result of a decrease in BCC. Therefore, it is necessary to eliminate the possibility of hypovolemia before starting treatment with olmesartan medoxomil.
Side effects:
From the side of the cardiovascular system: arterial hypotension, angina pectoris.
From the hemopoietic system: thrombocytopenia.
From the side of the central nervous system: vertigo, dizziness, headache, asthenic syndrome (fatigue, drowsiness, general malaise).
From the respiratory system: bronchitis, pharyngitis, rhinitis, cough.
From the digestive system: diarrhea, dyspepsia, gastroenteritis, abdominal pain, nausea, vomiting, increased activity of liver enzymes.
Dermatological reactions: skin itching, rash, angioedema, allergic dermatitis, swelling of the face, urticaria.
From the musculoskeletal system: arthritis, back pain, bone pain, muscle cramps, myalgia, increased CPK activity.
From the urinary system: hematuria, urinary tract infection.
From the side of metabolism: hypertriglyceridemia, hyperuricemia, hyperkalemia, increased levels of creatinine and urea in the blood serum, peripheral edema.
Storage method:
Store at a temperature not exceeding 30 degrees.
Package:
The cardboard box contains 3 blisters of 10 tablets, paper instructions.
